loading page

Successful pembrolizumab treatment of microsatellite instability-high intrahepatic cholangiocarcinoma: A case report
  • +6
  • YUKI IKEDA,
  • Michihiro Ono,
  • Ginji Omori,
  • Saki Ameda,
  • Michiko Yamada,
  • Tomoyuki Abe,
  • Shigeyuki Fujii,
  • Miri Fujita,
  • Masahiro Maeda
YUKI IKEDA
Shinnittetsu Muroran Sogo Byoin
Author Profile
Michihiro Ono
Shinnittetsu Muroran Sogo Byoin
Author Profile
Ginji Omori
Shinnittetsu Muroran Sogo Byoin
Author Profile
Saki Ameda
Shinnittetsu Muroran Sogo Byoin
Author Profile
Michiko Yamada
Shinnittetsu Muroran Sogo Byoin
Author Profile
Tomoyuki Abe
Shinnittetsu Muroran Sogo Byoin
Author Profile
Shigeyuki Fujii
Shinnittetsu Muroran Sogo Byoin
Author Profile
Miri Fujita
Shinnittetsu Muroran Sogo Byoin
Author Profile
Masahiro Maeda
Shinnittetsu Muroran Sogo Byoin
Author Profile

Abstract

Pembrolizumab is considered to be an effective therapy for patients with microsatellite instability (MSI)-high cancer. Here, we report a case of MSI-high cholangiocarcinoma effectively treated with pembrolizumab. MSI status should be actively evaluated in patients with cholangiocarcinoma.

Peer review status:ACCEPTED

15 Jan 2021Submitted to Clinical Case Reports
16 Jan 2021Submission Checks Completed
16 Jan 2021Assigned to Editor
29 Jan 2021Reviewer(s) Assigned
07 Feb 2021Review(s) Completed, Editorial Evaluation Pending
08 Feb 2021Editorial Decision: Revise Minor
11 Feb 20211st Revision Received
15 Feb 2021Submission Checks Completed
15 Feb 2021Assigned to Editor
15 Feb 2021Review(s) Completed, Editorial Evaluation Pending
21 Feb 2021Editorial Decision: Accept